Alzheon Inc. is the latest company to take a stab at treating Alzheimer's disease with a small molecule inhibitor of beta amyloid aggregation. The company has an improved version of a previously unsuccessful compound and plans to test it in a subset of patients it hopes will respond better than the general patient population.

Alzheon's compound is a variant of Alzhemed tramiprosate, which failed a Phase III AD trial by Bellus Health Inc. (formerly Neurochem Inc.) in 2007.